SCHEMBL3765062

SCHEMBL3765062

COc1ccccc1CNc1ccccc1-c1[c]nccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 10/20 0.47
CYP3A4 P08684 10/20 0.47
CYP2D6 P10635 10/20 0.47
CYP2C19 P33261 9/20 0.47
TSHR P16473 9/20 0.47
HSD17B10 Q99714 6/20 0.47
ALOX15 P16050 5/20 0.47
GAA P10253 2/20 0.46
USP2 O75604 3/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
CLK4 Q9HAZ1 3/20 0.44
CYP2C9 P11712 3/20 0.44
TP53 P04637 2/20 0.44
HIF1A Q16665 2/20 0.44
MAPK1 P28482 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751860 0.78 SGMS2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL1971146 0.78 ALDH1A1 (0.44) CYP1A2CYP3A4CYP2D6HSD17B10GAA
SCHEMBL8872302 0.72 L3MBTL1 (0.58) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3757718 0.71 LTA4H (0.44) CYP3A4ALDH1A1KDM4EMAPTMEN1
SCHEMBL8871279 0.70 ALDH1A1 (0.58) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5626734 0.69 L3MBTL1 (0.67) L3MBTL1HSD17B10GAAALDH1A1KDM4E
SCHEMBL5545750 0.69 L3MBTL1 (0.67) L3MBTL1CYP3A4CYP2D6TSHRGAA
SCHEMBL3758955 0.69 TRPA1 (0.35) L3MBTL1CYP2D6LMNA
SCHEMBL3760092 0.69 KDM4E (0.38) L3MBTL1TSHRHSD17B10GAAUSP2
SCHEMBL4765574 0.68 PDE5A (0.46) ALDH1A1KDM4EMAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA L3MBTL1 1887/4885CYP1A2 3200/4885CYP3A4 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.